Logo - springer
Slogan - springer

Medicine - Surgery | Gastric Cancer – incl. option to publish open access

Gastric Cancer

Gastric Cancer

Editor-in-Chief: Y. Kitagawa; G. de Manzoni

ISSN: 1436-3291 (print version)
ISSN: 1436-3305 (electronic version)

Journal no. 10120

$99.00 Personal Rate e-only for the Americas
Get Subscription

Online subscription, valid from January through December of current calendar year

Immediate access to this year's issues via SpringerLink

1 Volume(-s) with 6 issue(-s) per annual subscription

Automatic annual renewal

More information: >> FAQs // >> Policy

1 August 2017

Instructions to Authors

Gastric Cancer, a joint official journal of the international Gastric Cancer Association and the Japanese Gastric Cancer Association, publishes significant studies related to stomach neoplasms. Original articles (up to 4000 words, excluding references, with no more than seven figures/tables in total), Case reports (up to 1500, excluding references, with no more than seven figures/tables in total), Short communications (up to 1500 words, excluding references, with no more than four figures/tables in total), and Technical notes (up to 1500 words, excluding references, with no more than seven figures/tables in total) will be peer-reviewed for publication on the understanding that the study has not been submitted simultaneously to or accepted by another journal. The criteria for acceptance are originality and high scientific quality. Review articles (up to 5000 words, excluding references, with no more than seven figures/tables in total) are in principle solicited by the Editor, but unsolicited manuscripts will also be considered. Letters to the Editor (up to 500 words, excluding references, with no figure/table) commenting on articles published in the journal or expressing views on topics of gastric cancer are welcomed. Meeting reports, at the request of the Editor, will include summaries of symposia or consensus achieved in the congresses of related associations.

Clinical Trial Registration 

Any clinical trial for which patient enrollment began on or after January 1, 2014 must be registered. Authors have 6 months from the first patient enrollment to register the trial, but Gastric Cancer recommends registration prior to enrollment. This registration policy applies to prospective, randomized, controlled trials only.
Gastric Cancer follows the International Committee of Medical Journal Editors (ICMJE), which uses the World Health Organization's definition of a clinical trial. The ICMJE defines a clinical trial as "Any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes.' Health-related interventions include any intervention used to modify a biomedical or health-related outcome (for example, drugs, surgical procedures, devices, behavioral treatments, dietary interventions, and process-of-care changes). Health outcomes include any biomedical or health-related measures obtained in patients or participants, including pharmacokinetic measures and adverse events. Purely observational studies (those in which the assignment of the medical intervention is not at the discretion of the investigator) will not require registration."
The ICMJE lists the following registries as fully compliant:
Australian New Zealand Clinical Trials Registry
ISRCTN Register
UMIN Clinical Trials Registry
Netherlands Trial Register
Brazilian Clinical Trials Registry (ReBec)
Chinese Clinical Trial Registry (ChiCTR)
Clinical Research Information Service (CRiS), Republic of Korea
Clinical Trials Registry - India (CTRI)
Cuban Public Registry of Clinical Trials(RPCEC)
EU Clinical Trials Register (EU-CTR)
German Clinical Trials Register (DRKS)
Iranian Registry of Clinical Trials (IRCT)
Japan Primary Registries Network (JPRN)
Thai Clinical Trials Registry (TCTR)
Pan African Clinical Trial Registry (PACTR)
Sri Lanka Clinical Trials Registry (SLCTR)
Upon submission, authors must provide the registration identification number and the URL for the trial's registry.
Authors can post their results in clinical trial registries as part of these requirements without it being considered previously published or overlapping publication.
Authors also must agree to submit the original protocol upon request from the editorial committee.

Ethical Standards 

Gastric Cancer has adopted the Uniform Requirements for Manuscripts (URM) established by the International Committee of Medical Journal Editors (http://www.icmje.org/). The editors reserve the right to reject manuscripts that do not comply with the below-mentioned requirements. The author will be held responsible for false statements or failure to fulfill the below-mentioned requirements.
  • Human rights statement and informed consent:
For studies involving human subjects, the following statement should be included before the References section:
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent to be included in the study, or the equivalent, was obtained from all patients.
If doubts arise as to whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach, and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.
Identifying information of patients or human subjects – including their names, initials, addresses, admission dates, hospital numbers, or any other data that could be used to identify them – should not be published in written descriptions, photographs, or pedigrees unless the information is essential for scientific purposes and the patient (or their parent guardian) gives written informed consent to publish. If any identifying information about patients is included in the article, the following sentence should also be included:
Additional informed consent was obtained from all patients for which identifying information is included in this article.
For retrospective studies, the authors are not expected to have consent to participate, however, ethics approval is required. If the manuscript includes any potentially identifiable patient images or data, the authors also need to obtain informed consent.
  • Animal studies:
For studies with animals, include the following sentence before the References section:
All institutional and national guidelines for the care and use of laboratory animals were followed.
For articles that do not contain studies with human or animal subjects performed by any of the authors, while it is not absolutely necessary, we recommend to include the following sentence, just to make sure that readers are aware that there are no ethical issues with human or animal subjects:
This article does not contain any studies with human or animal subjects performed by any of the authors.

Disclosure of potential conflicts of interest 

Authors must disclose all relationships or interests that could have direct or potential influence or impart bias on the work. Although an author may not feel there is any conflict, disclosure of relationships and interests provides a more complete and transparent process, leading to an accurate and objective assessment of the work. Awareness of a real or perceived conflicts of interest is a perspective to which the readers are entitled. This is not meant to imply that a financial relationship with an organization that sponsored the research or compensation received for consultancy work is inappropriate. Examples of potential conflicts of interests that are directly or indirectly related to the research may include but are not limited to the following:
  • Research grants from funding agencies (please give the research funder and the grant number)
  • Honoraria for speaking at symposia
  • Financial support for attending symposia
  • Financial support for educational programs
  • Employment or consultation
  • Support from a project sponsor
  • Position on advisory board or board of directors or other type of management relationships
  • Multiple affiliations
  • Financial relationships, for example equity ownership or investment interest
  • Intellectual property rights (e.g. patents, copyrights and royalties from such rights)
  • Holdings of spouse and/or children that may have financial interest in the work
In addition, interests that go beyond financial interests and compensation (non-financial interests) that may be important to readers should be disclosed. These may include but are not limited to personal relationships or competing interests directly or indirectly tied to this research, or professional interests or personal beliefs that may influence your research.
The corresponding author collects the conflict of interest disclosure forms from all authors. In author collaborations where formal agreements for representation allow it, it is sufficient for the corresponding author to sign the disclosure form on behalf of all authors. The “ICMJE Uniform Disclosure Form for Potential Conflicts of Interest” available at http://www.icmje.org/downloads/coi_disclosure.pdf should be used.
The corresponding author will include a summary statement in the text of the manuscript in a separate section before the reference list, that reflects what is recorded in the potential conflict of interest disclosure form(s).
See below examples of disclosures:
Funding: This study was funded by X (grant number X).
Conflict of Interest: Author A has received research grants from Company A. Author B has received a speaker honorarium from Company X and owns stock in Company Y. Author C is a member of committee Z.
If no conflict exists, the authors should state:
Conflict of Interest: The authors declare that they have no conflict of interest.

Prerequisites for publication 

Certification form: A certification form, which is available at: http://www.springer.com/10120, must be submitted to the journal’s editorial office by uploading it as a PDF file at the same time you submit your manuscript via Editorial Manager.
IMPORTANT: The reviewing process starts only upon receipt of the Certification Form.

Manuscript submission via Editorial Manager 

Authors should submit their manuscripts to Gastric Cancer online. Please log in directly at: https://www.editorialmanager.com/gcan and upload your manuscript following the instructions given on the screen. Please use the Help option to see the most recently updated system requirements.

Preparation of manuscript 

Manuscript format and style should be in accordance with the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” (http://www.icmje.org). Type the manuscript double-space throughout with margins of at least 25mm. Number pages consecutively, beginning with the title page.
  • Title page:
The title page should carry 1) the type of article (e.g., original article, case report, etc.) 2) the title of the article; 3) the names of authors; 4) the name of the department(s) and institution(s) to which the work should be attributed; 5) the name and address of the author responsible for correspondence about the manuscript, with phone and fax numbers and e-mail address; 6) a short running head of no more than 40 characters (count letters and spaces); and 7) the word count of the article (please note the word limit for each type of article).
  • Abstract, mini-abstract, and key words:
The second page should carry an abstract of no more than 250 words. In addition, a miniabstract summarizing the significant conclusion of the study within 30 words should be submitted to appear in the table of contents. The abstracts of Original articles should be structured into four paragraphs: Background, Methods, Results, and Conclusions. Authors should provide three to five key words using terms from the medical subject headings (MeSH) list of Index Medicus.
  • References:
References should be numbered consecutively in the order in which they are first mentioned in the text. Identify references in text, tables, and legends by Arabic numerals in square brackets on the line, e.g., Ames et al. [1] reported...
Restrict citations, as far as possible, to papers written in English or with an English abstract. Use the style of the examples below, which are based on the formats used by the U.S. National Library of Medicine (NLM) in Index Medicus (http://www.nlm.nih.gov). List the first six authors followed by et al. The references must be verified by the authors against the original documents.
1. Journal article
Jacobson MA, Zegans M, Pavan PR, O’Donnell JJ, Sattler F, Rao N, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet. 1997;349:1443–5.
2. Journal article by DOI
Mitchell AJ, Vaze A, Rao S. Clinical diagnosis of depression in primary care: a meta-analysis. Lancet. 2009. doi: 10.1016/S0140-6736(09)60879-5.
3. Book chapter
Lefor AT, Flowers JL, Bailey RW. Laparoscopy in gastrointestinal malignancies. In: Wanebo HJ, editor. Surgery for gastrointestinal cancer: a multidisciplinary approach. 2nd ed. Philadelphia: Lippincott-Raven Publisher; 1997. pp. 145–59.
  • Tables:
Type each table with double spacing on a separate page. Number tables consecutively in the order of their first citation in the text and supply a brief title for each. Give each column a short or abbreviated heading. Place explanatory matter in footnotes, not in the heading. Footnotes to tables should be indicated by superscript lower-case letters (or asterisks for significance values and other statistical data) and included beneath the table body. Explain in footnotes all nonstandard abbreviations that are used in each table. Identify statistical measures of variations, such as standard deviation and standard error of the mean.
  • Figures:
All figures should be cited in the text and numbered consecutively throughout. Letters, numbers, and symbols should be clear and even throughout and of sufficient size that when reduced for publication each item will still be legible. Figure parts should be identified by lowercase roman letters (a, b, etc.). If illustrations are supplied with uppercase labeling, lowercase letters will still be used in the figure legends and citations. Color figures will always be published in color in the online version. In print, however, they will appear in color only if the author agrees to make a contribution to printing costs (¥ 140,000 per article). For more information about preparing illustrations, please refer to the artwork guidelines available at the end of this document.
  • Legends for figures:
Type legends for figures using double spacing, starting on a separate page, with Arabic numerals corresponding to the illustrations. When symbols, arrows, numbers, or letters are used to identify parts of the illustrations, identify and explain each one clearly in the legend.
  • Units of measurement:
Measurements of length, height, weight, and volume should be reported in metric units (meter, kilogram, or liter) or their decimal multiples. All hematologic and clinical chemistry measurements should be reported using the metric system of the International System of Units (SI).
  • Abbreviations and symbols:
Use only standard abbreviations. Avoid abbreviations in the title and abstract. The full term for which an abbreviation stands should precede its first use in the text unless it is a standard unit of measurement.

Case report 

Gastric Cancer publishes case reports with new findings. The following will be considered for publication. (A) Cases that have an important clinical impact: 1) Remarkable effects of a new therapy for gastric cancer; 2) Previously unreported adverse events in treatments for gastric cancer; 3) Novel suggestions or pitfalls in diagnosing gastric cancer; (B) Cases that may provide significant clues to the etiology or natural history of gastric cancer:
1) Combinations of gastric cancer and other diseases in which molecular biological findings provide new etiological information; 2) Previously unreported subtypes, syndromes, or familial accumulations of gastric cancer; 3) Untreated disappearance or long-term stable conditions of gastric cancer, including proof; 4) Previously unreported metastatic or progressive patterns of gastric cancer.
Reports of the following cases will not be accepted for publication. 1) Coincidental combination of gastric cancer and other diseases with no new etiological information;
2) Rare gastric cancer with no new findings;
3) Exceptional effects of conventional treatments without data explaining these results.
Provide an unstructured abstract of no more than 150 words. The text should not exceed 1,500 words (excluding references), and only essential figures and/or tables should be provided (no more than 5 items).
Authors of the report should be only those who made substantial contributions to the study. When histological findings play a key role in the report, a pathologist should be included as an author. Information that can identify patients must be omitted, or if in a figure, carefully masked.

Electronic supplementary material 

Electronic supplementary material will be published in the online version only.
It may consist of
・Information that cannot be printed: animations, video clips, sound recordings
・Information that is more convenient in electronic form: sequences, spectral data, etc.
・Large original data, e.g. additional tables, illustrations, etc.
・Supply all supplementary material in standard file formats.
・Please include in each file the following information: article title, journal name, author names; affiliation and e-mail address of the corresponding author.
・To accommodate user downloads, please keep in mind that larger-sized files may require very long download times and that some users may experience other problems during downloading.
Audio, video, and animations
・Always use MPEG-1 (.mpg) format.
Text and presentations
・Submit your material in PDF format; .doc or .ppt files are not suitable for long-term viability.
・A collection of figures may also be combined in a PDF file.
・Spreadsheets should be converted to PDF if no interaction with the data is intended.
・If the readers should be encouraged to make their own calculations, spreadsheets should be submitted as .xls files (MS Excel).
Specialized formats
・Specialized formats such as .pdb (chemical), .wrl (VRML), .nb (Mathematica notebook), and .tex can also be supplied.
Collecting multiple files
・It is possible to collect multiple files in a .zip or .gz file.
・If supplying any supplementary material, the text must make specific mention of the material as a citation, similar to that of figures and tables.
・Refer to the supplementary files as “Online Resource”, e.g., "... as shown in the animation (Online Resource 3)", “... additional data are given in Online Resource 4”.
・Name the files consecutively e.g. “ESM_3.mpg”, “ESM_4.pdf”.
・For each supplementary material, please supply a concise caption describing the content of the file.
Processing of supplementary files
・Electronic supplementary material will be published as received from the author without any conversion, editing, or reformatting.
In order to give people of all abilities and disabilities access to the content of your supplementary files, please make sure that
・The manuscript contain a descriptive caption for each supplementary material
・Video files do not contain anything that flashes more than three times per second (so that users prone to seizures caused by such effects are not put at risk)

Check list before submission 

– Word file is uploaded for the text.
– Certification Form signed by all coauthors to be uploaded at the same time you submit your manuscript via Editorial Manager.
–Title page included in the main document.
– Double spacing, 25-mm margins, page numbers.
– Mini-abstract of less than 30 words, in addition to an abstract and key words.
– References in the style of Index Medicus.
– Financial support, if any, should be mentioned in the Acknowledgments.

After acceptance 

Upon acceptance of your article you will receive a link to the special Author Query Application at Springer’s web page where you can sign the Copyright Transfer Statement online and indicate whether you wish to order Open Choice. Once the Author Query Application has been completed, your article will be processed and you will receive the proofs. You will also receive a separate e-mail for ordering offprints and printing of figures in color.
  • Open Choice publication
In addition to the normal publication process (whereby an article is submitted to the journal and access to that article is granted to customers who have purchased a subscription), Springer provides an alternative publishing option: Springer Open Choice. A Springer Open Choice article receives all the benefits of a regular subscription-based article, but in addition is made available publicly through Springer’s online platform SpringerLink. We regret that Springer Open Choice cannot be ordered for published articles.
Springer Open Choice [http://springer.com/openchoice]
In cooperation with the International Gastric Cancer Association and the Japanese Gastric Cancer Association, and the publisher, one year after the date of print publication, articles will become publicly available through SpringerLink regardless of whether the Springer Open Choice option is chosen initially.
  • Copyright transfer
Authors will be asked to transfer copyright of their articles to the international Gastric Cancer Association and the Japanese Gastric Cancer Association. This will ensure the widest possible protection and dissemination of information under copyright laws.
Open Choice articles do not require transfer of copyright as the copyright remains with the author. In opting for open access, they agree to the Springer Open Choice Licence.
  • Offprints
Offprints can be ordered by the corresponding author.
  • Color illustrations
Publication of color illustrations is free of charge.
  • Proof reading
The purpose of the proof is to check for typesetting or conversion errors and the completeness and accuracy of the text, tables and figures. Substantial changes in content, e.g., new results, corrected values, title and authorship, are not allowed without the approval of the Editor.
After online publication, further changes can only be made in the form of an Erratum, which will be hyperlinked to the article.
  • Online First
The article will be published online after receipt of the corrected proofs. This is the official first publication citable with the DOI. After release of the printed version, the paper can also be cited by issue and page numbers.

Open Choice 

Open Choice allows you to publish open access in more than 1850 Springer Nature journals, making your research more visible and accessible immediately on publication.
  • Increased researcher engagement: Open Choice enables access by anyone with an internet connection, immediately on publication.
  • Higher visibility and impact: In Springer hybrid journals, OA articles are accessed 4 times more often on average, and cited 1.7 more times on average*.
  • Easy compliance with funder and institutional mandates: Many funders require open access publishing, and some take compliance into account when assessing future grant applications.
It is easy to find funding to support open access – please see our funding and support pages for more information.
*) Within the first three years of publication. Springer Nature hybrid journal OA impact analysis, 2018.

Copyright and license term – CC BY

Open Choice articles do not require transfer of copyright as the copyright remains with the author. In opting for open access, the author(s) agree to publish the article under the Creative Commons Attribution License.

Artwork guidelines 

Electronic figure submission
• Supply all figures electronically.
• Indicate what graphics program was used to create the artwork.
• For vector graphics, the preferred format is EPS; for halftones, please use TIFF format. MS Office files are also acceptable.
• Vector graphics containing fonts must have the fonts embedded in the files.
• Name your figure files with "Fig" and the figure number, e.g., Fig1.eps.
Line art
• Definition: black and white graphic with no shading.
• Do not use faint lines and/or lettering and check that all lines and lettering within the figures are legible at final size.
• All lines should be at least 0.1 mm (0.3 pt) wide.
• Scanned line drawings and line drawings in bitmap format should have a minimum resolution of 1200 dpi.
Halftone art
• Definition: photographs, drawings, or paintings with fine shading, etc.
• If any magnification is used in the photographs, indicate this by using scale bars within the figures themselves.
• Halftones should have a minimum resolution of 300 dpi.
Combination art
• Definition: a combination of halftone and line art, e.g., halftones containing line drawing, extensive lettering, color diagrams, etc.
• Combination artwork should have a minimum resolution of 600 dpi.
Color art
• Color art is free of charge for online publication.
• If black and white will be shown in the print version, make sure that the main information will still be visible. Many colors are not distinguishable from one another when converted to black and white. A simple way to check this is to make a xerographic copy to see if the necessary distinctions between the different colors are still apparent.
• If the figures will be printed in black and white, do not refer to color in the captions.
• Color illustrations should be submitted as RGB (8 bits per channel).
Figure lettering
• To add lettering, it is best to use Helvetica or Arial (sans serif fonts).
• Keep lettering consistently sized throughout your final-sized artwork, usually about 2–3 mm (8–12 pt).
• Variance of type size within an illustration should be minimal, e.g., do not use 8-pt type on an axis and 20-pt type for the axis label.
• Avoid effects such as shading, outline letters, etc.
• Do not include titles or captions into your illustrations.
Figure numbering
• All figures are to be numbered using Arabic numerals.
• Figures should always be cited in the text in consecutive numerical order.
• Figure parts should be denoted by lowercase letters (a, b, c, etc.).
• If an appendix appears in your article/chapter and it contains one or more figures, continue the consecutive numbering of the main text. Do not number the appendix figures, "A1, A2, A3, etc." Figures in online appendices (Electronic supplementary Material) should, however, be numbered separately.
Figure captions
• Each figure should have a concise caption describing accurately what the figure depicts. Include the captions in the text file of the manuscript, not in the figure file.
• Figure captions begin with the term Fig. in bold type, followed by the figure number, also in bold type.
• No punctuation is to be included after the number, nor is any punctuation to be placed at the end of the caption.
• Identify all elements found in the figure in the figure caption; and use boxes, circles, etc., as coordinate points in graphs.
• Identify previously published material by giving the original source in the form of a reference citation at the end of the figure caption.
Figure placement and size
• When preparing your figures, size figures to fit in the column width.
• Figures should be 39 mm, 84 mm, 129 mm, or 174 mm wide and not higher than 234 mm.
• The publisher reserves the right to reduce or enlarge figures.
If you include figures that have already been published elsewhere, you must obtain permission from the copyright owner(s) for both the print and online format. Please be aware that some publishers do not grant electronic rights for free and that Springer will not be able to refund any costs that may have occurred to receive these permissions. In such cases, material from other sources should be used.
In order to give people of all abilities and disabilities access to the content of your figures, please make sure that
• All figures have descriptive captions (blind users could then use a text-to-speech
software or a text-to-Braille hardware)
• Patterns are used instead or in addition to colors for conveying information (color-blind users would then be able to distinguish the visual elements)
• Any figure lettering has a contrast ratio of at least 4.5:1.

Ethical Responsibilities of Authors 

This journal is committed to upholding the integrity of the scientific record. As a member of the Committee on Publication Ethics (COPE) the journal will follow the COPE guidelines on how to deal with potential acts of misconduct.
Authors should refrain from misrepresenting research results which could damage the trust in the journal, the professionalism of scientific authorship, and ultimately the entire scientific endeavour. Maintaining integrity of the research and its presentation can be achieved by following the rules of good scientific practice, which include:
  • The manuscript has not been submitted to more than one journal for simultaneous consideration.
  • The manuscript has not been published previously (partly or in full), unless the new work concerns an expansion of previous work (please provide transparency on the re-use of material to avoid the hint of text-recycling (“self-plagiarism”)).
  • A single study is not split up into several parts to increase the quantity of submissions and submitted to various journals or to one journal over time (e.g. “salami-publishing”).
  • No data have been fabricated or manipulated (including images) to support your conclusions
  • No data, text, or theories by others are presented as if they were the author’s own (“plagiarism”). Proper acknowledgements to other works must be given (this includes material that is closely copied (near verbatim), summarized and/or paraphrased), quotation marks are used for verbatim copying of material, and permissions are secured for material that is copyrighted.
    Important note: the journal may use software to screen for plagiarism.
  • Consent to submit has been received explicitly from all co-authors, as well as from the responsible authorities - tacitly or explicitly - at the institute/organization where the work has been carried out, before the work is submitted.
  • Authors whose names appear on the submission have contributed sufficiently to the scientific work and therefore share collective responsibility and accountability for the results.
  • Authors are strongly advised to ensure the correct author group, corresponding author, and order of authors at submission. Changes of authorship or in the order of authors are not accepted after acceptance of a manuscript.
  • Adding and/or deleting authors and/or changing the order of authors at revision stage may be justifiably warranted. A letter must accompany the revised manuscript to explain the reason for the change(s) and the contribution role(s) of the added and/or deleted author(s). Further documentation may be required to support your request.
  • Requests for addition or removal of authors as a result of authorship disputes after acceptance are honored after formal notification by the institute or independent body and/or when there is agreement between all authors.
  • Upon request authors should be prepared to send relevant documentation or data in order to verify the validity of the results. This could be in the form of raw data, samples, records, etc. Sensitive information in the form of confidential proprietary data is excluded.
If there is a suspicion of misconduct, the journal will carry out an investigation following the COPE guidelines. If, after investigation, the allegation seems to raise valid concerns, the accused author will be contacted and given an opportunity to address the issue. If misconduct has been established beyond reasonable doubt, this may result in the Editor-in-Chief’s implementation of the following measures, including, but not limited to:
  • If the article is still under consideration, it may be rejected and returned to the author.
  • If the article has already been published online, depending on the nature and severity of the infraction, either an erratum will be placed with the article or in severe cases complete retraction of the article will occur. The reason must be given in the published erratum or retraction note. Please note that retraction means that the paper is maintained on the platform, watermarked "retracted" and explanation for the retraction is provided in a note linked to the watermarked article.
  • The author’s institution may be informed.

Read this Journal on Springerlink

For authors and editors

  • Journal Citation Reports®
    2017 Impact Factor
  • 5.045
  • Aims and Scope

    Aims and Scope


    Gastric Cancer, a joint official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, publishes significant studies related to stomach neoplasms. The journal welcomes original articles, case reports, short communications, and technical notes, which will be peer-reviewed by the editorial board. Letters to the Editor commenting on articles published in the journal or expressing views on topics concerning gastric cancer are also welcomed. Review articles are in principle solicited by the Editor. Meeting reports will include summaries of symposia or consensus achieved in the congresses of related associations.
  • Submit Online
  • Open Choice - Your Way to Open Access
  • Instructions for Authors

    Instructions to Authors


  • Certification Form (pdf, 59 kB)
  • English Language Editing

    English Language Editing


  • Author Academy: Training for Authors
  • Copyright Information

    Copyright Information


    For Authors

    Submission of a manuscript implies: that the work described has not been published before (except in form of an abstract or as part of a published lecture, review or thesis); that it is not under consideration for publication elsewhere; that its publication has been approved by all co-authors, if any, as well as – tacitly or explicitly – by the responsible authorities at the institution where the work was carried out.

    Author warrants (i) that he/she is the sole owner or has been authorized by any additional copyright owner to assign the right, (ii) that the article does not infringe any third party rights and no license from or payments to a third party is required to publish the article and (iii) that the article has not been previously published or licensed. The author signs for and accepts responsibility for releasing this material on behalf of any and all co-authors. Transfer of copyright to The International Gastric Cancer Association and The Japanese Gastric Cancer Association becomes effective if and when a Copyright Transfer Statement is signed or transferred electronically by the corresponding author. After submission of the Copyright Transfer Statement signed by the corresponding author, changes of authorship or in the order of the authors listed will not be accepted by Springer.

    The copyright to this article, including any graphic elements therein (e.g. illustrations, charts, moving images), is assigned for good and valuable consideration to The International Gastric Cancer Association and The Japanese Gastric Cancer Association effective if and when the article is accepted for publication and to the extent assignable if assignability is restricted for by applicable law or regulations (e.g. for U.S. government or crown employees).

    The copyright assignment includes without limitation the exclusive, assignable and sublicensable right, unlimited in time and territory, to reproduce, publish, distribute, transmit, make available and store the article, including abstracts thereof, in all forms of media of expression now known or developed in the future, including pre- and reprints, translations, photographic reproductions and microform. Springer may use the article in whole or in part in electronic form, such as use in databases or data networks for display, print or download to stationary or portable devices. This includes interactive and multimedia use and the right to alter the article to the extent necessary for such use.

    Authors may self-archive the Author’s accepted manuscript of their articles on their own websites. Authors may also deposit this version of the article in any repository, provided it is only made publicly available 12 months after official publication or later. He/she may not use the publisher's version (the final article), which is posted on SpringerLink and other Springer websites, for the purpose of self-archiving or deposit. Furthermore, the Author may only post his/her version provided acknowledgement is given to the original source of publication and a link is inserted to the published article on Springer's website. The link must be accompanied by the following text: "The final publication is available at link.springer.com”.

    Prior versions of the article published on non-commercial pre-print servers like arXiv.org can remain on these servers and/or can be updated with Author's accepted version. The final published version (in pdf or html/xml format) cannot be used for this purpose. Acknowledgement needs to be given to the final publication and a link must be inserted to the published article on Springer's website, accompanied by the text "The final publication is available at link.springer.com". Author retains the right to use his/her article for his/her further scientific career by including the final published journal article in other publications such as dissertations and postdoctoral qualifications provided acknowledgement is given to the original source of publication.

    Author is requested to use the appropriate DOI for the article. Articles disseminated via springer.link.com are indexed, abstracted and referenced by many abstracting and information services, bibliographic networks, subscription agencies, library networks, and consortia.

    For Readers

    While the advice and information in this journal is believed to be true and accurate at the date of its publication, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may have been made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

    All articles published in this journal are protected by copyright, which covers the exclusive rights to reproduce and distribute the article (e.g., as offprints), as well as all translation rights. No material published in this journal may be reproduced photographically or stored on microfilm, in electronic data bases, video disks, etc., without first obtaining written permission from The International Gastric Cancer Association and The Japanese Gastric Cancer Association. The use of general descriptive names, trade names, trademarks, etc., in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

    Springer has partnered with Copyright Clearance Center’s RightsLink service to offer a variety of options for reusing Springer content. For permission to reuse our content please locate the material that you wish to use on SpringerLink.com or on SpringerImages.com and click on the permissions link or go to copyright.com and enter the title of the publication that you wish to use. For assistance in placing a permission request, Copyright Clearance Center can be connected directly via phone: +1-855-239-3415, fax: +1-978-646-8600, or e-mail: info@copyright.com.

    © The International Gastric Cancer Association and The Japanese Gastric Cancer Association



Services for the Journal

Alerts for this journal


Get the table of contents of every new issue published in Gastric Cancer.